Valneva SE

Valneva SE a specialty vaccine company develops manufactures and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; and VLA2001 an inactivated whole-virus COVID-19 vaccine. The company also develops VLA15 a vaccine candidate which is in Phase III clinical trial against Borrelia the bacterium that causes Lyme disease; VLA1553 a vaccine candidate which is in Phase III clinical trial against the chikungunya virus; VLA1554 a vaccine candidate targeting human metapneumovirus; and VLA2112 a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States Canada Germany Austria Nordics the United Kingdom France rest of European countries and internationally. Valneva SE has collaborations with Pfizer Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development manufacturing and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is based in Saint-Herblain France.